Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is also developing TP-04 for the treatment of Ocular Rosacea; TP-05 for potential Lyme disease prophylaxis; and community malaria reduction. In addition, the company develops lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Tarsus Pharmaceuticals, Inc.

Oppenheimer analyst Mazahir Alimohamed maintained a Buy rating on Tarsus Pharmaceuticals today and set a price target of $97.00. According to TipRa...

Oppenheimer Reaffirms Their Buy Rating on Tarsus Pharmaceuticals (TARS)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on UnitedHealth (UNH) and Tarsus Pharmaceuticals (TARS). UnitedHealt...

Analysts Offer Insights on Healthcare Companies: UnitedHealth (UNH) and Tarsus Pharmaceuticals (TARS)

An update from Tarsus Pharmaceuticals ( ($TARS) ) is now available. On July 13, 2026, Tarsus Pharmaceuticals, Inc. announced that Chief Commercial ...

Tarsus Pharmaceuticals Announces Chief Commercial Officer Transition

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Conmed (CNMD) and Tarsus Pharmaceuticals (TARS). Conmed (CNMD) Ne...

Analysts Offer Insights on Healthcare Companies: Conmed (CNMD) and Tarsus Pharmaceuticals (TARS)

Guggenheim analyst Eddie Hickman reiterated a Buy rating on Tarsus Pharmaceuticals today and set a price target of $90.00. According to TipRanks, H...

Guggenheim Sticks to Its Buy Rating for Tarsus Pharmaceuticals (TARS)

In a report released today, Jenna Davidner from Barclays maintained a Buy rating on Tarsus Pharmaceuticals, with a price target of $100.00. Accordi...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	TARS	$64.79	-0.83%	983.15K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	TARS	$64.79	-0.8%	983.15K
3
4
5
6

TARS

TARS

Get Tarsus Pharmaceuticals, Inc. Data in Excel

Get Tarsus Pharmaceuticals, Inc. Data in Excel